Sponsor

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

The Netherlands Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands

About the sponsor

Oncology research spans solid and haematological malignancies, with strong activity in pancreatic cancer, colorectal cancer, gastro-oesophageal cancer, cholangiocarcinoma, urothelial cancer, prostate cancer, breast cancer, melanoma, glioblastoma, and paediatric leukaemia.

Peritoneal metastases
Targeted therapy and immunotherapy
Image-guided surgery and PET imaging
Radiotherapy combinations
Paediatric and adult cancer care

Work in this area also includes neuroendocrine tumours, sarcomas, head and neck cancer, and carcinoma of unknown primary.

About Specializations

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) runs clinical trials in conditions such as Malignant melanoma, Glycogen storage disease type II, HIV infection, Oesophageal carcinoma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

85 clinical trials

HIV infection

Recruiting

A study to evaluate the effectiveness of lenalidomide, pyrimethamine, and topiramate in reducing the HIV reservoir in people living with HIV.

Registered drugNo placebo

A study to evaluate the effectiveness of lenalidomide, pyrimethamine, and topiramate in reducing the HIV reservoir in people living with HIV.

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Lenalidomide
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Gastric cancer

Recruiting

A study of irinotecan and a drug combination for patients with gastric cancer or gastroesophageal junction cancer undergoing surgery.

Registered drugNo placebo

A study of irinotecan and a drug combination for patients with gastric cancer or gastroesophageal junction cancer undergoing surgery.

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Irinotecan Hydrochloride Trihydrate
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Non-small cell lung cancer metastatic

Recruiting

Study of Different Dosing Schedules of Osimertinib in Patients with EGFR Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo

Study of Different Dosing Schedules of Osimertinib in Patients with EGFR Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Osimertinib
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Wheezing

Recruiting

Study of inhaled corticosteroids (beclometasone, fluticasone, budesonide) and salbutamol in children aged 1-6 years with episodic wheezing

Registered drugNo placebo

Study of inhaled corticosteroids (beclometasone, fluticasone, budesonide) and salbutamol in children aged 1-6 years with episodic wheezing

Registered drugNo placebo

The Netherlands

Participants:0–17 years
Substances:Budesonide
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Metastases to peritoneum

Recruiting

Evaluation of 68Ga-FAPI PET/CT scan effectiveness in monitoring treatment response in patients with peritoneal metastases receiving intraperitoneal chemotherapy

InvestigationalNo placebo

Evaluation of 68Ga-FAPI PET/CT scan effectiveness in monitoring treatment response in patients with peritoneal metastases receiving intraperitoneal chemotherapy

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Metastatic gastric cancer

Recruiting

Evaluating intraperitoneal irinotecan with systemic therapy in patients with gastric peritoneal metastases

Registered drugNo placebo

Evaluating intraperitoneal irinotecan with systemic therapy in patients with gastric peritoneal metastases

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Irinotecan Hydrochloride Trihydrate
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Oesophageal carcinoma+1

Recruiting

Study of drug combination therapy for patients with lymph node-positive esophageal and esophagogastric junction cancer using carboplatin, paclitaxel, fluorouracil, folinic acid, docetaxel and oxaliplatin

Registered drugNo placebo

Study of drug combination therapy for patients with lymph node-positive esophageal and esophagogastric junction cancer using carboplatin, paclitaxel, fluorouracil, folinic acid, docetaxel and oxaliplatin

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Renal transplant

Recruiting

Comparison of tacrolimus alone versus tacrolimus, Mycophenolate mofetil and prednisone combination in elderly kidney transplant patients to reduce infections

Registered drugNo placebo